Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 1;82(3):739-754.
doi: 10.1097/HEP.0000000000001202. Epub 2024 Dec 19.

Enhancing HBV-specific T cell responses through a combination of epigenetic modulation and immune checkpoint inhibition

Melanie Urbanek-Quaing  1   2   3   4 , Yin-Han Chou  1   3   4   5 , Manoj Kumar Gupta  3   5 , Katja Steppich  1   2   3   4   5 , Birgit Bremer  1 , Hagen Schmaus  1   3   4   5 , Katja Deterding  1 , Benjamin Maasoumy  1 , Heiner Wedemeyer  1   2   4 , Cheng-Jian Xu  3   5 , Anke R M Kraft  1   2   3   4   5 , Markus Cornberg  1   2   3   4   5
Affiliations

Enhancing HBV-specific T cell responses through a combination of epigenetic modulation and immune checkpoint inhibition

Melanie Urbanek-Quaing et al. Hepatology. .

Abstract

Background and aims: Chronic HBV infection exhausts HBV-specific T cells, develops epigenetic imprints that impair immune responses, and limits the effectiveness of immune checkpoint inhibitor monotherapy, such as anti-programmed cell death ligand-1 antibody (αPD-L1). This study aimed to determine whether the DNA methyltransferase inhibitor decitabine (DAC) could reverse these epigenetic imprints and enhance immune checkpoint inhibitor efficacy in restoring HBV-specific T cell responses.

Approach and results: We investigated HBV-specific T cell responses by 10-day in vitro stimulation of peripheral blood mononuclear cells (PBMCs) from patients with chronic HBV infection. PBMCs were stimulated with HBV core-specific overlapping peptide pools and HLA-A*02-restricted peptides, core 18 and pol 455 . The immunomodulatory effect of the DAC/αPD-L1 combination was assessed by flow cytometry, and our analysis included clinical characteristics, ex vivo DNA methylation of PBMCs, and IFNγ plasma levels.Treatment with DAC/αPD-L1 enhanced HBV-specific CD4 + T cell responses in a significant proportion of 53 patients, albeit with some variability. This effect was independent of the HBcrAg levels. Ex vivo DNA methylation revealed hypermethylation of key genes, such as IFNG among DAC-responders versus non-responders, supported by altered ex vivo IFNγ plasma levels. Further analysis of HBV-specific CD8 + T cell responses in 22 HLA-A*02-positive patients indicated distinct response patterns between core 18 and pol 455 stimulation, with pol 455 -specific CD8 + T cells showing increased susceptibility to DAC/αPD-L1, surpassing the αPD-L1 monotherapy response.

Conclusions: The combination of DAC/αPD-L1 shows promise in improving HBV-specific T cell responses in vitro , highlighting the potential of remodeling exhaustion-associated epigenetic signatures to enhance HBV-specific T cell restoration and suggesting a novel immunotherapeutic avenue for chronic HBV infection.

Keywords: DNA methyltransferase inhibitor; HBV; T cell exhaustion; epigenetics; immune checkpoint inhibition.

PubMed Disclaimer

References

    1. Polaris Observatory Collaborators. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: A modelling study. Lancet Gastroenterol Hepatol. 2023;8:879–907.
    1. Cornberg M, Lok ASF, Terrault NA, Zoulim F; 2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B—Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. J Hepatol. 2020;72:539–557.
    1. Sandmann L, Cornberg M. Towards eradication of HBV: Treatment approaches and status of clinical trials. Curr Opin Pharmacol. 2021;60:232–240.
    1. Blank CU, Haining WN, Held W, Hogan PG, Kallies A, Lugli E, et al. Defining “T cell exhaustion”. Nat Rev Immunol. 2019;19:665–674.
    1. Belk JA, Daniel B, Satpathy AT. Epigenetic regulation of T cell exhaustion. Nat Immunol. 2022;23:848–860.

MeSH terms

LinkOut - more resources